Atrasentan delays progression time of metastatic PCa

September 1, 2004

New Orleans--Treatment with the endothelin receptor antagonist atrasentan (Xinlay) significantly delays time to progression in patients with metastatic, hormone-refractory prostate cancer, according to a meta-analysis of pooled data from two large trials.